Researchers used multiple AI models to evaluate EHR data from more than 322,000 heart failure patients. By identifying these subtypes, the group thinks clinicians could perform better risk assessments and make more informed treatment decisions. 

Bruce Wilkoff, MD, director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic, said the new device could be "an important advancement for heart failure patients."

The FDA has previously approved the SGLT2 inhibitor in patients with HFrEF, but not HFmrEF or HFpEF

Teams from three universities have received four-year research grants to examine the relationship between chronic stress and CVD. Each team plans to study the issue from a different angle.

The device, described as the "world's smallest heart pump," has received the FDA's breakthrough device designation for two indications. 

The company has seen significant improvements in revenue and the number of centers actively using its technology.

A new laser imaging technology may be able to determine which donor hearts are viable for transplant and which will result in poor outcomes, without the need for coronary angiography or use of contrast agents that can damage an explanted heart.

Certain uses of the CentriMag acute circulatory support system were previously limited to six hours, but the FDA has now cleared long-term treatment so that clinicians have more time to provide high-quality care.